Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
The study raises concerns about the effectiveness of cancer drugs, as genetic differences may affect how someone responds to a drug.
New initiative will help health care providers navigate the process of submitting expanded access requests.
ASCO and Friends of Cancer Research proposed new eligibility guidelines in 2017.
Eighty percent of medications that receive accelerated approval don’t extend overall survival.
Women make up half of the HIV population, but the virus affects them differently than men.
Federal researchers describe two paths to a vaccine—and one of them uses high-tech computers to design a vaccine candidate!
Clinical trials often exclude key patient populations, including children and people living with HIV or hepatitis B or C.
Researchers believe their greater understanding of leukemia stem cells will lead to more treatment options for people with the blood cancer.
Can data from more than 1 million Americans accelerate research and medical breakthroughs that benefit everyone?
After his first bout with acute lymphoblastic leukemia, Connor McMahon wanted to give other children hope.
Less than 5 percent of Black patients were involved in trials for 24 out of 31 cancer drugs approved since 2015.
Study findings underscore the need for uniform care and treatment.
The actress and SU2C ambassador encourages diverse groups of cancer patients to participate in clinical trials.
Trials of immunotherapy drug for multiple myeloma suspended after patient deaths.
Find out about all the known risks, benefits, rights and responsibilities.
The search for a safe, effect HIV vaccine continues.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.